Current Locations:Home > PRODUCTS > IBI308

IBI308-Monoclonal Antibody for Tumor Immunotherapy

Indicated for the treatment of multiple solid tumors such as lung cancer, gastric cancer, melanoma and kidney cancer etc.; there are over 4.3 million new cases of cancer in China according to Cancer statistics in China, 2015, which renders a huge burden on the community. As an immune-oncology agent, a breakthrough class of drug in oncology, IBI308 has great potential in prolonging patients’ lifespans. This product is expected to be a best-in-class.  Innovent has licensed the global IP for IBI308 to Eli Lilly and Company.

Copyright © 2011- Innovent Biologics, Inc.
Powered by RuiXi